Status:
UNKNOWN
Molecular Evaluation in Metastatic Breast Cancer
Lead Sponsor:
Odense University Hospital
Conditions:
Metastatic Breast Cancer
Molecular Imaging
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
Background: Despite that up 90% of patients with early-stage breast cancer receives adjuvant treatment, there are still about 300 patients diagnosed with primary metastatic breast cancer (MBC) and abo...
Detailed Description
Background Breast cancer is the most frequent malignant disease in Danish women with about 4,500 new cases per year and about 60,000 women living after a diagnosis of breast cancer (1). After lung can...
Eligibility Criteria
Inclusion
- Women
- Age \> 18
- Suspicion of recurrence of earlier breast cancer or new breast cancer diagnose with high risk of metastatic disease
- Life expectancy \> 3 month
- Signed statement of consent
Exclusion
- Men
- Pregnancy
- Severe Medical conditions
- severe mental og psychological conditions
- contraindications for MRI (for patients with bone metastasis)
- treatment for other malignant diseases within the last 5 years prior to inclusion (except carcinoma in situ cervicis uteri and basal cell carcinoma (BCC))
Key Trial Info
Start Date :
September 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2021
Estimated Enrollment :
270 Patients enrolled
Trial Details
Trial ID
NCT03358589
Start Date
September 1 2017
End Date
August 31 2021
Last Update
May 25 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Marianne Vogsen
Odense, Funen, Denmark, DK-5000